Back to Agenda
Session 7: Strategies for Global Drug Development
Session Chair(s)
Younglim Kim, PhD
Director General, National Institute of Food & Drug Safety (NIFDS), Korea, Republic of
Speaker(s)
CMC Information recommended for INDs and NDAs
Giljong Kang
, C & O Pharma Consultants, United States
Hanmi Footprints & Reshaping for Global Clinical Trials
Kyounghee Seo
, Hanmi , Korea, Republic of
Patient Centric Drug Development and Approval Factors Affecting Dose and Dosing Regimen
Hae-Young Ahn, PhD
President, Ahn Bio, United States
Ho Jung Oh
Director NIFDS, Ministry of Food and Drug Safety, Korea, Republic of
Have an account?